Mural Oncology PLC MURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.89
- Day Range
- $3.72–3.90
- 52-Week Range
- $3.23–17.00
- Bid/Ask
- $3.71 / $4.12
- Market Cap
- $63.63 Mil
- Volume/Avg
- 103,449 / 211,840
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 117
- Website
- https://www.muraloncology.com
Valuation
Metric
|
MURA
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
MURA
|
---|---|
Quick Ratio | 10.99 |
Current Ratio | 11.27 |
Interest Coverage | — |
Quick Ratio
MURA
Profitability
Metric
|
MURA
|
---|---|
Return on Assets (Normalized) | −77.39% |
Return on Equity (Normalized) | −89.35% |
Return on Invested Capital (Normalized) | −82.80% |
Return on Assets
MURA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bgtsfckrd | Zdp | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ykzqnmggl | Wxvbmd | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kkwwwwbm | Lhgkrz | $108.2 Bil | |
MRNA
| Moderna Inc | Mmymhbgcy | Lhwhr | $50.9 Bil | |
ARGX
| argenx SE ADR | Qwcgtnd | Dnjlg | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zrddrdss | Pjwh | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sgcxbmd | Mmnlkx | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bwlvdzmd | Jctvcm | $14.6 Bil | |
INCY
| Incyte Corp | Wdnfkfsb | Dzrsrsb | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bvyfrzgrkb | Rmlyjz | $12.3 Bil |